TORONTO, Nov. 8, 2023 /CNW/ - LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), the leading whole-person wellbeing solution for employers, health plans and other organizations, announced today its financial and operational results for the three and nine months ended September 30, 2023. All references to dollar values in this press release are in Canadian dollars, unless otherwise indicated.
"Our third quarter Adjusted EBITDA margin of 25% increased versus the 2022 comparable period of 24%, demonstrating that we have established a consistent revenue base for our business, and a well-managed cost structure," said Michael Held, CEO and Founder of LifeSpeak. "As we look ahead, our pipeline of sales opportunities remains robust, and, coupled with our stable and consistent quarterly financial results, provides us with confidence in our business prospects going forward."
Consolidated Business Highlights for the Three Months Ended September 30, 2023
(All capitalized terms not defined herein shall have the meaning ascribed to them in the Management's Discussion and Analysis for the three months ended September 30, 2023, unless otherwise stated)
1 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "ARR" |
ARR, Consolidated Net Dollar Retention Rate and Logo Retention Rate Breakdown
ARR was approximately $51.5 million as at September 30, 2023, with core enterprise client ARR of approximately $43.6 million.
ARR Breakdown | ||||||||
In C$ thousands, unless otherwise noted | Q3-2022 | Q4-2022 | Q1-2023 | Q2-2023 | Q3-2023 | YoY | ||
Total Enterprise ARR | 43,065 | 43,860 | 44,824 | 44,035 | 43,619 | 1 % | ||
Total Embedded Solutions & Other ARR | 9,088 | 8,978 | 8,488 | 8,155 | 7,913 | (13 %) | ||
Total ARR | 52,153 | 52,838 | 53,312 | 52,190 | 51,532 | (1 %) |
Additionally, stability in the Company's Number of Clients continued year-over-year. Total Number of Clients was 988 as at September 30, 2023, compared to 987 as at September 30, 2022.
Number of Clients | |||||||
Q3-2022 | Q4-2022 | Q1-2023 | Q2-2023 | Q3-2023 | YoY | ||
Total Enterprise Clients | 968 | 983 | 972 | 979 | 973 | 1 % | |
Total Embedded Solutions Clients | 19 | 19 | 18 | 17 | 15 | (21 %) | |
Total Number of Clients | 987 | 1,002 | 990 | 996 | 988 | 0 % |
3 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition of "Adjusted EBITDA" and "Adjusted EBITDA Margin" |
Consolidated Net Dollar Retention Rate4 for the quarter was 88%, a 10% increase from the same period in 2022, primarily due to the reference period no longer being affected by the loss of the large, embedded solutions client as first disclosed in the management discussion and analysis for the first quarter of 2022, offset by an increase in overall enterprise client churn. Net Dollar Retention Rate for enterprise clients was approximately 88% as at September 30, 2023.
Logo Retention Rate5 was 81% as at September 30, 2023 compared to 87% for the comparable period in 2022. As retention is measured on a last twelve-month basis, the lower Logo Retention Rate is primarily attributable to the loss of smaller enterprise client logos within the portfolio of customers.
Internal initiatives focused on cross-selling products to existing clients, and strong uptake to date in the opportunity to discuss multiproduct solutions with at-risk clients is trending positively.
In addition to the continued focus on revenue growth, the Company continues to monitor the cost base of the business and optimize for efficiencies where possible. This focus on costs has allowed the Company to continue to realize cost savings following the acquisitions. In the third quarter of 2023, the Company generated annualized cost savings of approximately $0.3 million, bringing total annualized savings implemented following the acquisitions to approximately $12.8 million.
4 See "Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators" for a definition, "Net Dollar Retention Rate". |
Financial Results for the Three and Nine Months Ended September 30, 2023:
Selected Consolidated Financial Information (in thousands of Canadian dollars) | Three Months Ended September 30, | Nine Months Ended September 30, | ||
2023 | 2022 | 2023 | 2022 | |
Revenue | 12,898 | 12,766 | 39,458 | 33,616 |
Less: | ||||
Content development costs | 1,264 | 1,179 | 3,801 | 3,613 |
Gross Profit | 11,634 | 11,587 | 35,657 | 30,003 |
Gross Profit Margin (1) | ||||
Gross Profit Margin | 90 % | 91 % | 90 % | 89 % |
Deduct Expenses: | ||||
Sales and marketing | 2,476 | 2,662 | 8,123 | 9,686 |
General and administrative | 6,230 | 6,485 | 19,376 | 20,309 |
Share-based compensation | 751 | 1,587 | 3,607 | 7,431 |
Foreign exchange (gain) loss | (1,626) | (4,032) | 267 | (3,591) |
Amortization and depreciation | 3,925 | 3,971 | 12,058 | 10,224 |
11,756 | 10,673 | 43,431 | 44,058 | |
Loss before undernoted | (123) | 914 | (7,773) | (14,056) |
Acquisition and other costs (2) | - | 686 | - | 8,435 |
Changes in fair value of on contingent consideration | 5 | (2,216) | (3,533) | (3,951) |
Finance expense, net | 2,546 | 3,804 | 7,210 | 6,675 |
Loss before income taxes | (2,674) | (1,360) | (11,450) | (25,215) |
Income taxes recovery | (692) | (405) | (2,863) | (2,051) |
Net Loss | (1,982) | (955) | (8,587) | (23,164) |
Earning (loss) per share - basic | (0.04) | (0.02) | (0.17) | (0.46) |
Earnings (loss) per share- diluted | (0.04) | (0.02) | (0.17) | (0.46) |
Non-IFRS Measures | ||||
EBITDA (3) | 3,797 | 6,415 | 7,817 | (8,316) |
Adjusted EBITDA (4) | 3,251 | 3,078 | 10,269 | 5,872 |
Adjusted Net Income (Loss) (5) | (2,528) | (4,292) | (6,135) | (8,975) |
Adjusted earnings (loss) per share – basic (6) | (0.05) | (0.08) | (0.12) | (0.18) |
Adjusted earnings (loss) per share – diluted (7) | (0.05) | (0.08) | (0.12) | (0.18) |
Notes: | |
(1) | Gross profit margin is calculated as gross profit divided by revenue for the relevant period. |
(2) | Acquisition and other costs are comprised of a portion of the costs related to the entry into of the Company's pre-IPO credit agreement and costs related to recapitalization distributions and the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters and costs and expenses in connection with the Company's acquisitions (for the purposes of calculating Adjusted EBITDA and Adjusted Net Income). |
(3) | "EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(4) | "Adjusted EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(5) | "Adjusted Net Income (Loss)" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(6) | "Adjusted earnings (loss) per share – basic" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(7) | "Adjusted earnings (loss) per share – diluted" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
Conference Call Notification
The Company will hold a conference call to provide a business update on Wednesday, November 8, 2023, at 8:00 a.m. ET hosted by:
A question-and-answer session will follow the business update.
CONFERENCE CALL DETAILS | |
DATE: | Wednesday, November 8, 2023 |
TIME: | 8:00 a.m. ET |
DIAL-IN NUMBERS: | 1.833.950.0062 or 1.833.470.1428 |
REFERENCE NUMBER: | 785825 |
This live call is also being webcast and can be accessed by going to: https://events.q4inc.com/attendee/323796959
An archived telephone replay of the call will be available for two weeks by dialing 1.226.828.7578 or 1.866.813.9403 and entering access code 803206.
Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators
LifeSpeak supplements its results of operations determined in accordance with IFRS with certain non-IFRS financial measures, non-IFRS ratios and key performance indicators that the Company believes are useful to investors, lenders and others in assessing its performance and which highlight trends its core business that may not otherwise be apparent when relying solely on IFRS measures. LifeSpeak management also uses non-IFRS measures, non-IFRS ratios and key performance indicators for purposes of comparison to prior periods, to prepare annual operating budgets, for the development of future projections and earnings growth prospects, to measure the profitability of ongoing operations and in analyzing our financial condition, business performance and trends. As such, these measures and indicators are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective, including how it evaluates its financial performance and how it manages its capital structure. LifeSpeak also believes that securities analysts, investors and other interested parties frequently use these non-IFRS measures, non-IFRS ratios and key performance indicators in the evaluation of issuers. These non-IFRS measures, non-IFRS ratios and key performance indicators are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and may include or exclude certain items as compared to similar IFRS measures, and such measures may not be comparable to similarly-titled measures reported by other companies. Accordingly, these measures and indicators should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.
Non-IFRS Measures, Non-IFRS Ratios and Reconciliation of Non-IFRS Measures
The Company uses non-IFRS measures, including "EBITDA", "Adjusted EBITDA", "Adjusted Net Income (Loss)", and the non-IFRS ratios, including "Adjusted earnings (loss) per share – basic", "Adjusted earnings (loss) per share – diluted" and "Adjusted EBITDA Margin". This press release also makes reference to "Annual Recurring Revenue" or "ARR", "Net Dollar Retention Rate", "Number of Clients" and "Logo Retention Rate", which are key performance indicators used in our industry.
EBITDA and Adjusted EBITDA
"EBITDA" is defined as net income or loss before income tax expenses, finance costs and depreciation and amortization.
"Adjusted EBITDA" is defined as EBITDA before acquisition and other costs, share based compensation, foreign exchange loss (gain), impairment of goodwill, changes in fair value of contingent consideration, synergies realized and additional one time items. These non-cash and non-recurring costs are independent events which are non-recurring in nature and incurred over several financial periods.
"Adjusted EBITDA Margin" is calculated as Adjusted EBITDA divided by revenue for the relevant period.
(In thousands of Canadian dollars) | Three Months Ended September 30, | Nine Months Ended September 30, | ||||
2023 | 2022 | 2023 | 2022 | |||
Net income (loss) | (1,982) | (955) | (8,587) | (23,164) | ||
Add: | ||||||
Amortization and depreciation expense | 3,925 | 3,971 | 12,058 | 10,224 | ||
Finance expense | 2,546 | 3,804 | 7,210 | 6,675 | ||
Income tax expense (recovery) | (692) | (405) | (2,863) | (2,051) | ||
EBITDA (1) | 3,797 | 6,415 | 7,817 | (8,316) | ||
Add: | ||||||
Acquisition and other costs (2) | - | 686 | - | 8,435 | ||
Share-based compensation | 751 | 1,587 | 3,607 | 7,431 | ||
Foreign exchange loss (gain) | (1,626) | (4,032) | 267 | (3,591) | ||
Changes in fair value of contingent consideration | 5 | (2,216) | (3,533) | (3,951) | ||
Synergies realized (3) | 61 | 472 | 598 | 2,410 | ||
Additional one-time costs (4) | 263 | 166 | 1,514 | 3,454 | ||
Adjusted EBITDA (5) | 3,251 | 3,078 | 10,269 | 5,872 | ||
Adjusted EBITDA Margin (6) | 25 % | 24 % | 26 % | 17 % | ||
Notes: | |
(1) | "EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(2) | Acquisition and other costs are comprised of a portion of the costs related to the entry into of the Company's pre-IPO credit agreement and costs related to recapitalization distributions and the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters and costs and expenses in connection with the Company's acquisitions, including potential transaction bonuses (for the purposes of calculating Adjusted EBITDA and Adjusted Net Income). |
(3) | Synergies realized relates to the impact of the full period of cost synergies related to the reduction of employees and professional services in relation to acquisitions. |
(4) | One-time costs related to IPO specific adjustments, acquisitions specific adjustments and transition costs related to the Wellbeats acquisition. |
(5) | "Adjusted EBITDA" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(6) | "Adjusted EBITDA Margin" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
Adjusted Net Income (Loss) / Adjusted Earnings (Loss)
"Adjusted Net Income (Loss)" is defined as net income (loss) before acquisition and other costs, share based compensation, foreign exchange loss (gain), impairment of goodwill, changes in fair value of contingent consideration, synergies realized and additional one-time items. These non-cash and non-recurring costs are independent events which are non-recurring in nature and incurred over several financial periods.
"Adjusted earnings (loss) per share – basic" is defined as Adjusted Net Income (Loss) divided by the weighted average number of shares outstanding – basic for the relevant period.
"Adjusted earnings (loss) per share – diluted" is defined as Adjusted Net Income (Loss) divided by the weighted average number of shares outstanding – diluted for the relevant period.
(In thousands ofCanadian dollars) | Three Months Ended September 30, | Nine Months Ended September 30, | |||
2023 | 2022 | 2023 | 2022 | ||
Net income (loss) | (1,982) | (955) | (8,587) | (23,164) | |
Add: | |||||
Acquisition and other costs (1) | - | 686 | - | 8,435 | |
Share-based compensation | 751 | 1,587 | 3,607 | 7,431 | |
Foreign exchange loss (gain) | (1,626) | (4,032) | 267 | (3,591) | |
Changes in fair value of contingent consideration | 5 | (2,216) | (3,533) | (3,951) | |
Synergies realized (2) | 61 | 472 | 598 | 2,410 | |
Additional one-time costs (3) | 263 | 166 | 1,514 | 3,454 | |
Adjusted Net Income (Loss) (4) | (2,528) | (4,292) | (6,135) | (8,975) | |
Adjusted earnings per share – basic (5) | (0.05) | (0.08) | (0.12) | (0.18) | |
Adjusted earnings per share – diluted (6) | (0.05) | (0.08) | (0.12) | (0.18) |
Notes: | |
(1) | Acquisition and other costs are comprised of a portion of the costs related to the entry into of the Company's pre-IPO credit agreement and costs related to recapitalization distributions and the investment by the Institutional Investors, costs and expenses in connection with the Company's IPO and related matters and costs and expenses in connection with the Company's acquisitions, including potential transaction bonuses (for the purposes of calculating Adjusted EBITDA and Adjusted Net Income). |
(2) | Synergies realized relates to the impact of the full period of cost synergies related to the reduction of employees and professional services in relation to acquisitions. |
(3) | One-time costs related to IPO specific adjustments, acquisitions specific adjustments and transition costs related to the Wellbeats acquisition. |
(4) | "Adjusted Net Income (Loss)" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures and Key Performance Indicators." |
(5) | "Adjusted earnings (loss) per share – basic" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
(6) | "Adjusted earnings (loss) per share – diluted" has the meaning ascribed herein under "Cautionary Note Regarding Non-IFRS Measures, Non-IFRS Ratios and Key Performance Indicators". |
Key Performance Indicators
Annual Recurring Revenue
"Annual Recurring Revenue" or "ARR" is equal to the annualized value of contracted recurring revenue from all clients of our platform at the date being measured. Contracted recurring revenue is revenue generated from clients who are, as of the date being measured, party to contracts with LifeSpeak. Such revenue is annualized by: (i) in the case where a contract was in existence for the entire month, multiplying recognized revenue in the calendar month of the date measured by 12; and (ii) in the case where a contract was entered into mid-month, extrapolating recognized revenue at the date measured for the entire calendar month, and then multiplying by 12. Contract lengths typically range from one to three years and, based on our past experience, the vast majority of clients renew their contracts upon expiry. ARR is mainly comprised of revenue from enterprise and embedded solutions and includes revenue from small business and ancillary services (comprised of portals, kits and events purchased by our existing clients or distributed through our channel partners). ARR provides a consolidated measure by which we can monitor the longer-term trends in our business.
"enterprise client ARR" is ARR at a particular date attributable to enterprise clients.
Net Dollar Retention Rate
"Net Dollar Retention Rate" for a period is defined by considering a cohort of clients at the beginning of the period, and dividing the ARR from enterprise and embedded solutions attributable to that cohort at the end of the period, by the ARR from enterprise and embedded solutions attributable to that cohort at the beginning of the period. Net Dollar Retention Rate provides a consolidated measure by which we can monitor the percentage of recurring ARR retained from existing clients.
Number of Clients
"Number of Clients" is defined as the number of clients at the end of any particular period as the number of enterprise clients and clients of our embedded solutions for which the term of services has not ended, or with which the Company is negotiating contract renewal and which meet a minimum revenue threshold.
Logo Retention Rate
"Logo Retention Rate" for a period is defined by considering a cohort of clients at the beginning of the period, and dividing the Number of Clients from that cohort at the end of the period, by the Number of Clients from that cohort at the beginning of the period. Logo Retention Rate provides a consolidated measure by which the Company can monitor the percentage of contracted clients retained every year.
About LifeSpeak Inc.
LifeSpeak is the leading whole-person-wellbeing platform for employers and other organizations that brings together digital education with human support. Our suite of wellbeing products allows organizations to provide best-in-class content and expertise that scales, meeting each individual wherever they are on their personal wellbeing journeys. As the parent company to LIFT Digital, ALAViDA Health, Torchlight, and Wellbeats, LifeSpeak provides in-depth expertise across mental health, wellness, physical fitness, substance use, and caregiving. With more than 30 years of collective experience working directly with Fortune 500 companies, government agencies, insurance providers, and others across the globe, we understand the complexities of addressing wellbeing within organizations, which is why our digital and data-driven approach provides insights that uncover gaps in wellbeing at the organizational level, ultimately enhancing performance outcomes. To learn more, follow LifeSpeak on LinkedIn (http://www.linkedin.com/company/lifespeak-inc), or visit www.LifeSpeak.com.
Forward-Looking Information
This press release may contain "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking information may relate to the Company's future business, financial outlook and anticipated events or results and may include information regarding the Company's financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, and the Company's plans and objectives. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "budget", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "anticipates", "does not anticipate", "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Particularly, information regarding the Company's expectations of future results, revenue growth, ARR, EBITDA, adjusted EBITDA margin, adjusted EBITDA, adjusted Net Income (Loss), adjusted Earnings (Loss), Number of Clients, Net Dollar Retention Rate, Logo Retention Rate, performance, synergies, achievements, prospects, industry trends, advancement of its strategy and acceleration of its growth, the use of proceeds of the loan advance from the credit agreement with Beedie, amortization or opportunities, including for cross-selling, or the markets in which the Company operates is forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding possible future events or circumstances.
This forward-looking information and other forward-looking information are based on opinions, estimates and assumptions in light of the Company's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. These opinions, estimates and assumptions include, but are not limited to, the following: the Company's ability to build its market share and enter new geographies; the total available market for its products; the Company's ability to retain key personnel; the Company's ability to maintain and expand geographic scope; the Company's ability to execute on its expansion plans; the Company's ability to continue investing in infrastructure to support its growth and brand recognition; the Company's ability to maintain its existing client base; the Company's ability to continue maintaining and enhancing its technological infrastructure and functionality of its platform; to the Company's ability to obtain financing on acceptable terms; the Company's ability to effectively integrate its recent acquisitions; the Company's ability to generate sufficient cash to deleverage, the impact of competition; the changes and trends in the Company's industry or the global economy; and changes in laws, rules, regulations, and global standards.
The risks and uncertainties that may affect forward-looking statements include, among others: performance of the market sectors that the Company serves; general market performance including capital market conditions and availability and cost of credit; foreign currency and exchange risk; impact of factors such as increased pricing pressure and possible margin compression; the regulatory and tax environment; that expected cost and revenue synergies are not realized within the expected timeframe or at all; that revenue, ARR, EBITDA margin and cash flow expectations are not met for any number of reasons; political, labour or supplier disruptions; that our clients face recessionary pressures, and other risks detailed from time to time in the Company's filings with Canadian provincial securities regulators, including the risk factors which are described in greater detail under "Risk Factors" in the Company's annual information form for the fiscal year ended 2022. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not currently known to the Company or that the Company currently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information.
Accordingly, prospective investors should not place undue reliance on forward-looking information. The forward-looking information contained in this press release represents the Company's expectations as of the date of this press release (or as the date it is otherwise stated to be made) and is subject to change after such date. However, the Company disclaims any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable Canadian securities laws.
All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements. Prospective investors should read this entire press release and consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of an investment in the Company.
Last Trade: | C$0.37 |
Daily Volume: | 0 |
Market Cap: | C$21.880M |
November 07, 2024 May 08, 2024 March 21, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB